Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
NCT00254891
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Little Rock, Alaska +190 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00735696
Completed
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2014
Locations: ImClone Investigational Site, Beverly Hills, California +8 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
NCT02004093
Completed
This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/25/2014
Locations: Not set, Bruxelles, Not set +33 locations
Conditions: Ovarian Cancer
Register for Updates
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
NCT01166542
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: University of Alabama at Birmingham, Birmingham, Alabama +76 locations
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00300885
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Birmingham, Alabama +201 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
NCT00111007
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Birmingham, Alabama +65 locations
Conditions: Melanoma
Register for Updates
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
NCT00507429
Terminated
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2014
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +40 locations
Conditions: Anaplastic Thyroid Cancer
Register for Updates
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
NCT01843829
Unknown
About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less than a quarter have resectable disease at diagnosis. There is a general lack of consistency in the standard of care for patients across UK hospitals. Patients are either treated with a) chemotherapy followed by surgical removal of the tumour, or b) chemoradiotherapy followed by removal of the tumour by surgery, as part of their standard of care. Recent research supports the latter treatment, as chemoradio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2014
Locations: Bristol Oncology and Haematology Centre, Bristol, Not set +11 locations
Conditions: Oesophageal Cancer
Register for Updates
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
NCT00522834
Terminated
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. Subjects will participate in up to 2 weeks of screening during which time... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2014
Locations: Arizona Cancer Center, Tucson, Arizona +100 locations
Conditions: Melanoma
Register for Updates
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002894
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of platinum-based chemotherapy with or without paclitaxel in treating patients with relapsed ovarian epithelial cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
12/18/2013
Locations: Middlesex Hospital- Meyerstein Institute, London, England
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
NCT00003998
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for treating ovarian epithelial cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus paclitaxel with that of carboplatin plus docetaxel in treating patients who have ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2013
Locations: C.R.C. Beatson Laboratories, Glasgow, Scotland
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer
NCT00004077
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, ifosfamide, and cisplatin in treating patients who have metastatic testicular cancer that has recurred following treatment.
Gender:
MALE
Ages:
Between 16 years and 64 years
Trial Updated:
12/18/2013
Locations: Velindre Hospital, Cardiff, Wales
Conditions: Testicular Germ Cell Tumor
Register for Updates